Impact of timing of urinary catheter removal on voiding dysfunction after radical hysterectomy for early cervical cancer.

Cervical Cancer Hysterectomy Postoperative Care

Journal

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
ISSN: 1525-1438
Titre abrégé: Int J Gynecol Cancer
Pays: England
ID NLM: 9111626

Informations de publication

Date de publication:
08 Jul 2022
Historique:
pmc-release: 08 01 2024
entrez: 8 7 2022
pubmed: 9 7 2022
medline: 9 7 2022
Statut: aheadofprint

Résumé

To evaluate whether the timing of postoperative urinary catheter removal is associated with voiding dysfunction after radical hysterectomy for early cervical cancer within contemporary surgical practice. We performed an institutional retrospective cohort study of patients who underwent Piver type II-III open or minimally invasive radical hysterectomy for early-stage cervical cancer (International Federation of Gynecology and Obstetrics (FIGO) 2009 stage IA1 with lymphovascular invasion to stage IIA) between January 2006 and December 2019. We compared voiding dysfunction (inability to spontaneously void with a post-void residual <100 mL after catheter removal) and outcomes based on postoperative timing of urinary catheter removal using univariate and multivariate logistic regressions. Among 234 patients, 86 (36.8%) underwent open surgery and 112 (47.9%) used enhanced recovery after surgery (ERAS) pathways. 29 (12.4%) patients had urinary catheter removal between 1-5 days postoperatively (group 1), 141 (60.3%) between 6-10 days (group 2), and 64 (27.3%) between 11-15 days (group 3). The overall rate of voiding dysfunction was 11.5%, with no difference between group 1 (17.2%), group 2 (11.3%), and group 3 (9.4%) (p=0.54). Group 1 had a significantly shorter time from surgery to spontaneous voiding (4 days, IQR 3-5 days) compared with group 2 (8 days, IQR 7-10 days) and group 3 (13 days, IQR 11-15 days) (p<0.01). There was no difference in hospital length of stay, urinary tract infection, or re-admission due to a genitourinary complication within 60 days of surgery based on timing of catheter removal. On multivariate analysis, the odds of voiding dysfunction did not differ by tumor size, type of hysterectomy, cancer stage, surgical approach, ERAS timeframe, or timing of catheter removal group. There was no difference in voiding dysfunction or postoperative genitourinary complications based on timing of urinary catheter removal after radical hysterectomy. Early catheter removal should be considered in this population.

Identifiants

pubmed: 35803608
pii: ijgc-2022-003654
doi: 10.1136/ijgc-2022-003654
pmc: PMC9825680
mid: NIHMS1815802
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA101642
Pays : United States

Informations de copyright

© IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: SPH reports funding support for the present manuscript from the MD Anderson Cancer Center Support Grant from the National Cancer Institute of the National Institutes of Health (NIH/NCI P30 CA016672) and the T32 training grant (NIH/NCI CA101642). LAM reports consulting fees from Bristol Meyers Squibb, advisory board participation for GlaxoSmithKline, and stocks in Crisper, Invitae, and Bristol-Myers Squibb. MF is a consultant/speaker for Stryker, a consultant for Stryker, Astrellas, and Seagen, and receives research funding from Astra Zeneca and GlaxoSmithKline. PTR reports payments as Editor-in-Chief of the International Journal of Gynecological Cancer. The remaining authors report no conflicts of interest.

Références

J Nippon Med Sch. 2021 Nov 17;88(5):386-397
pubmed: 32741908
Can J Anaesth. 2015 Feb;62(2):120-30
pubmed: 25391733
Am J Obstet Gynecol. 2011 Sep;205(3):225.e1-7
pubmed: 21684517
PLoS One. 2014 Apr 18;9(4):e94116
pubmed: 24748015
Gynecol Oncol. 2016 May;141(2):371-378
pubmed: 26906066
Neurourol Urodyn. 2015 Apr;34(4):309-15
pubmed: 24519734
Int Urogynecol J. 2015 Jul;26(7):947-57
pubmed: 25432634
J Gynecol Oncol. 2018 Jul;29(4):e59
pubmed: 29770629
Am J Clin Oncol. 2019 Oct;42(10):783-788
pubmed: 31490195
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Gynecol Oncol. 2021 Mar;160(3):729-734
pubmed: 33419610
Surgery. 2014 Feb;155(2):211-6
pubmed: 24331759
Gynecol Oncol. 1991 Nov;43(2):98-102
pubmed: 1743565
J Surg Oncol. 2020 Dec;122(7):1498-1505
pubmed: 32779228
JAMA Oncol. 2020 Jul 1;6(7):1019-1027
pubmed: 32525511
Gynecol Oncol. 2011 Aug;122(2):264-8
pubmed: 21592548
N Engl J Med. 2018 Nov 15;379(20):1905-1914
pubmed: 30379613
J Gynecol Oncol. 2015 Apr;26(2):90-9
pubmed: 25872890
Int J Gynecol Cancer. 2019 May;29(4):651-668
pubmed: 30877144
Crit Rev Oncol Hematol. 2003 Dec;48(3):287-93
pubmed: 14693341
Am J Obstet Gynecol. 2009 Nov;201(5):485.e1-9
pubmed: 19879394
Am J Obstet Gynecol. 2020 Mar;222(3):249.e1-249.e10
pubmed: 31586602
Int J Gynaecol Obstet. 2009 May;105(2):103-4
pubmed: 19367689
J Obstet Gynaecol. 2019 Aug;39(6):788-792
pubmed: 31006315
Am J Obstet Gynecol. 1991 Jan;164(1 Pt 1):7-14
pubmed: 1986630
Arch Gynecol Obstet. 2012 Oct;286(4):1007-10
pubmed: 22648448
J Obstet Gynaecol. 2017 Oct;37(7):970-972
pubmed: 28782402
Gynecol Oncol. 2016 Nov;143(2):352-356
pubmed: 27519967
N Engl J Med. 2018 Nov 15;379(20):1895-1904
pubmed: 30380365

Auteurs

Sarah Huepenbecker (S)

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

María Clara Santía (MC)

Department of Obstetrics and Gynecology, Asociacion de Medicos y Profesionales del Hospital Aleman, Buenos Aires, Buenos Aires, Argentina.

Ross Harrison (R)

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Ricardo Dos Reis (R)

Department of Gynecologic Oncology, Hospital de Cancer de Barretos, Barretos, Sao Paolo, Brazil.

Rene Pareja (R)

Gynecology, Instituto Nacional de Cancerologia, Bogota, Colombia.
Gynecologic Oncology, Clinica de Oncología Astorga, Medellin, Colombia.

Maria D Iniesta (MD)

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Larissa A Meyer (LA)

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Michael Frumovitz (M)

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Andres Zorrilla-Vaca (A)

Department of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Anesthesia, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Pedro T Ramirez (PT)

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA peramire@mdanderson.org.

Classifications MeSH